# Phase 1/2 esophageal cancer trials recruiting: 29 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials in phase 1/2 for esophageal cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 esophageal cancer trials: 29 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/esophageal-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 29
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 14, 2026 | NCT07818018 | A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | Memorial Sloan Kettering Cancer Center | Phase 1/2 | Recruiting | Esophageal Cancer, Advanced Esophageal Cancer, Gastric Cancer, Advanced Gastric Cancer, Gastroesophageal Junction... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818018) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| May 19, 2026 | NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | Northwestern University | Phase 1/2 | Recruiting | Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant... | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594626) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| January 26, 2026 | NCT07367516 | Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1/2 | Recruiting | Esophageal Cancer | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07367516) |
| January 14, 2026 | NCT07341737 | SL-28 for Advanced Solid Tumours | Second Life Therapeutics | Phase 1/2 | Recruiting | Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341737) |
| August 7, 2025 | NCT07108855 | Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic... | University Medical Center Groningen | Phase 1/2 | Recruiting | Esophageal Carcinoma, Gastric Carcinoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07108855) |
| July 11, 2025 | NCT07061704 | Oncolytic Virus in Esophageal Squamous Cell Carcinoma | Sichuan University | Phase 1/2 | Recruiting | Esophageal Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07061704) |
| April 24, 2025 | NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Tanabe Pharma America, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06943521) |
| December 31, 2024 | NCT06753747 | A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma | West China Hospital | Phase 1/2 | Recruiting | Esophagus Cancer | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06753747) |
| November 29, 2024 | NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | Perspective Therapeutics | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck... | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06710756) |
| August 1, 2024 | NCT06532799 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer | Essen Biotech | Phase 1/2 | Recruiting | Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma, Esophageal Cancer, Esophageal Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06532799) |
| June 24, 2024 | NCT06469944 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally... | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06469944) |
| June 6, 2024 | NCT06445972 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06445972) |
| April 24, 2024 | NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Cancer Research UK | Phase 1/2 | Recruiting | Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms... | 167 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06380816) |
| March 7, 2024 | NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Lantheus Medical Imaging | Phase 1/2 | Recruiting | Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06298916) |
| February 2, 2024 | NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | ModeX Therapeutics, An OPKO Health Company | Phase 1/2 | Recruiting | Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric... | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06239194) |
| November 13, 2023 | NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Revolution Medicines, Inc. | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | 534 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06128551) |
| September 21, 2023 | NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Neonc Technologies, Inc. | Phase 1/2 | Recruiting | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal... | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06047379) |
| July 13, 2023 | NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | Cancer Research UK | Phase 1/2 | Recruiting | Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05944237) |
| July 10, 2023 | NCT05937438 | Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma | Anhui Provincial Hospital | Phase 1/2 | Recruiting | Esophageal Carcinoma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05937438) |
| October 24, 2022 | NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid... | Marengo Therapeutics, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus... | 366 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05592626) |
| April 8, 2022 | NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer... | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Esophageal Squamous Cell Carcinoma | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05319730) |
| January 11, 2022 | NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | Second Affiliated Hospital of Guangzhou Medical University | Phase 1/2 | Recruiting | Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05187338) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 3 |
| Essen Biotech | 2 |
| Cancer Research UK | 2 |
| West China Hospital | 1 |
| Arvinas Inc. | 1 |
| Neonc Technologies, Inc. | 1 |
| Centre Hospitalier Universitaire de Besancon | 1 |
| Perspective Therapeutics | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 1 |
| University Medical Center Groningen | 1 |
| Second Affiliated Hospital of Guangzhou Medical University | 1 |
| Sichuan University | 1 |
| ModeX Therapeutics, An OPKO Health Company | 1 |
| VM Oncology, LLC | 1 |
| Marengo Therapeutics, Inc. | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| [Lantheus Medical Imaging](https://specstream.ai/data/clinical-trials/company/lantheus-medical-imaging) | 1 |
| [Tanabe Pharma America, Inc.](https://specstream.ai/data/clinical-trials/company/tanabe-pharma-america-inc) | 1 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| [LG Chem](https://specstream.ai/data/clinical-trials/company/lg-chem) | 1 |
| Northwestern University | 1 |
| Anhui Provincial Hospital | 1 |
| Second Life Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 15 |
| China | 11 |
| France | 6 |
| Italy | 5 |
| Germany | 4 |
| Netherlands | 3 |
| Spain | 3 |
| United Kingdom | 3 |
| Brazil | 3 |
| Chile | 3 |
| Norway | 3 |
| South Korea | 3 |
| Switzerland | 3 |
| Taiwan | 3 |
| Japan | 2 |
| Thailand | 2 |
| Puerto Rico | 2 |
| Belgium | 1 |
| Singapore | 1 |
| Turkey (Türkiye) | 1 |
| Canada | 1 |
| Australia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Escrow companies in the United States](https://specstream.ai/data/businesses/escrow-companies/united-states)
- [Bookkeeping firms in the United States](https://specstream.ai/data/businesses/bookkeeping-firms/united-states)
- [Urgent care clinics in the United States](https://specstream.ai/data/businesses/urgent-care-clinics/united-states)
- [Preschools in the United States](https://specstream.ai/data/businesses/preschools/united-states)
- [Jamaican restaurants in the United States](https://specstream.ai/data/businesses/jamaican-restaurants/united-states)
- [Emergency departments in the United States](https://specstream.ai/data/businesses/emergency-departments/united-states)
